Response of human dental pulp capped with MTA and calcium hydroxide powder.
OBJECTIVE
To compare the response of human dental pulp capped with a mineral trioxide aggregate (MTA) and Ca(OH)2 powder.


METHODS
Pulp exposures were performed on the occlusal floor of 40 permanent premolars. The pulp was then capped with either Ca(OH)2 powder (CH) or MTA and restored with resin composite. After 30 days (groups CH30 and MTA30) and 60 days (groups CH60 and MTA60), the teeth were extracted and processed for HE and categorized in a histological score system. The data were subjected to Kruskal-Wallis and Conover tests (alpha = 0.05).


RESULTS
In regard to dentin bridge formation, CH30 showed a tendency towards superior performance compared to MTA30 (p > 0.05), although the products showed comparable results at day 60. In the item "Inflammation" and "General State of the Pulp" (p > 0.05), CH showed a tendency towards presenting a higher inflammatory response. In the item "Other Pulpal Findings," MTA and Ca(OH)2 showed equal and excellent performance after 30 and 60 days (p > 0.05).


CONCLUSIONS
After 30 days, Ca(OH)2 powder covered with calcium hydroxide cement showed faster hard tissue bridge formation compared to MTA. After 60 days, Ca(OH)2 powder or MTA materials showed a similar and excellent histological response with the formation of a hard tissue bridge in almost all cases with low inflammatory infiltrate.
Accorinte
M L R
ML
Department of Dental Materials, School of Dentistry, University Brás Cubas, São Paulo, SP, Brazil.
Loguercio
Alessandro D
AD
Reis
Alessandra
A
Carneiro
E
E
Grande
R H M
RH
Murata
S S
SS
Holland
R
R
D000293:Adolescent; D000328:Adult; D017607:Aluminum Compounds / Q000627:therapeutic use*; D001641:Bicuspid; D017610:Calcium Compounds / Q000627:therapeutic use*; D002126:Calcium Hydroxide / Q000627:therapeutic use*; D003188:Composite Resins; D003764:Dental Materials / Q000627:therapeutic use*; D003782:Dental Pulp / Q000187:drug effects* / Q000473:pathology; D003785:Dental Pulp Capping / Q000379:methods*; D003789:Dental Pulp Exposure / Q000628:therapy; D003793:Dental Restoration, Permanent; D003809:Dentin, Secondary / Q000187:drug effects / Q000473:pathology; D004338:Drug Combinations; D015726:Giant Cells / Q000473:pathology; D006801:Humans; D008264:Macrophages / Q000473:pathology; D008422:Materials Testing; D010087:Oxides / Q000627:therapeutic use*; D020011:Protective Agents / Q000627:therapeutic use*; D011671:Pulpitis / Q000473:pathology; D017640:Silicates / Q000627:therapeutic use*; D013997:Time Factors; D014098:Toothache / Q000209:etiology
D017607:Aluminum Compounds; D017610:Calcium Compounds; D003188:Composite Resins; D003764:Dental Materials; D004338:Drug Combinations; D010087:Oxides; D020011:Protective Agents; D017640:Silicates; C086631:mineral trioxide aggregate; D002126:Calcium Hydroxide